Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Yu, Xue Q ^a   Chen, Wendy H ^b   O'Connell, Dianne L ^a  

^a CANCER RESEARCH DIVISION   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT RESPONSE; INCIDENCE; MIDDLE AGED; MORTALITY; POISSON DISTRIBUTION; REGISTER; RISK FACTOR; SURVIVAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEW SOUTH WALES; POISSON DISTRIBUTION; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952491185     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-231     Document Type: Article

References (46)

1. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008, 59:237-250. 10.1146/annurev.med.59.060906.220345, 18186705.
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328(14):1002-1006. 10.1056/NEJM199304083281404, 7680764.
3. Australian Drug Evaluation Committee - 197th meeting recommendations. , http://www.tga.gov.au/docs/html/adec/adec0197.htm
4. Australian Drug Evaluation Committee - 220th meeting recommendations. , http://www.tga.gov.au/docs/html/adec/adec0220.htm
5. Tracey E, Alam N, Chen W, Bishop J. Cancer in New South Wales: Incidence and Mortality 2006. 2008, Sydney: Cancer Institute NSW.
6. Medicare Australia: PBS Statistics. , http://www.medicare.gov.au/provider/pbs/stats.jsp
7. Berkson J, Gage RP. Calculation of survival rates for cancer. Proc Staff Meet Mayo Clin 1950, 25(11):270-286.
8. Coleman M, Aylin P, . (eds) Death certification and mortality statistics: an international perspective. 2000, London: The Stationery Office, 1, (eds).
9. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961, 6:101-121.
10. Chiang C. Introduction to stochastic processes in biostatistics. 1968, New York: Wiley.
11. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996, 78(9):2004-2010. 10.1002/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-#, 8909323.
12. Dickman PW. Estimating and modelling relative survival using SAS. , http://www.pauldickman.com/rsmodel/sas_colon/
13. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63(8):803-843. 10.2165/00003495-200363080-00005, 12662126.
14. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadie M, Spinelli JJ. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007, 110(2):695-708. 10.1182/blood-2006-11-051672, 1924473, 17389762.
15. Jaffe E, Harris N, Stein H, Vardiman J. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. 2001, Lyon, France: IARC Press.
16. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D, Whelan S, . (eds) International Classification of Diseases for Oncology. 2000, Geneva, Switzerland: World Health Organisation, 3, (eds).
17. Percy C, Van Holten V, Muir C, . (eds) International classification of diseases for oncology. 1990, Geneva, Switzerland: World Health Organisation, 2, (eds).
18. Yu XQ, O'Connell DL, Gibberd RW, Coates AS, Armstrong BK. Trends in survival and excess risk of death after diagnosis of cancer in 1980-1996 in New South Wales, Australia. Int J Cancer 2006, 119(4):894-900. 10.1002/ijc.21909, 16550595.
19. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004, 23(1):51-64. 10.1002/sim.1597, 14695639.
20. Yu XQ, O'Connell DL, Gibberd RW, Smith DP, Dickman PW, Armstrong BK. Estimating regional variation in cancer survival: a tool for improving cancer care. Cancer Causes Control 2004, 15(6):611-618. 10.1023/B:CACO.0000036165.13089.e8, 15280640.
21. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000, 19(3):335-351. 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z, 10649300.
22. Statistical Research and Applications Branch NCI Joinpoint Regression Program. 2008, 3.3, Statistical Research and Applications Branch NCI.
23. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Neste E, Salles G, Gaulard P. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346(4):235-242. 10.1056/NEJMoa011795, 11807147.
24. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104(10):3064-3071. 10.1182/blood-2004-04-1323, 15284112.
25. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106(12):3725-3732. 10.1182/blood-2005-01-0016, 16123223.
26. Cronin DP, Harlan LC, Clegg LX, Stevens JL, Yuan G, Davis TA. Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma. Hematol Oncol 2005, 23(2):73-81. 10.1002/hon.747, 16170828.
27. Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, Nadler LM, de Vita VT, Lister TA, Armitage JO. Lymphoma classification--the gap between biology and clinical management is closing. Blood 1996, 88(11):4085-4089.
28. Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev 2006, 15(4):630-638. 10.1158/1055-9965.EPI-05-0549, 16614102.
29. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med 2006, 260(2):103-117. 10.1111/j.1365-2796.2006.01677.x, 16882274.
30. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008, 44(10):1345-1389. 10.1016/j.ejca.2007.12.015, 18280139.
31. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Should we use incidence, survival or mortality to assess breast cancer trends in European women?. Nat Clin Pract Oncol 2006, 3(5):228-229. 10.1038/ncponc0489, 16682983.
32. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld Y, Eimermacher H. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104(3):634-641. 10.1182/blood-2003-06-2095, 15016643.
33. Johnson PW. Survival from non-Hodgkin lymphoma in England and Wales up to 2001. Br J Cancer 2008, 99(Suppl 1):S107-S109. 10.1038/sj.bjc.6604606, 2557527, 18813239.
34. Wolf M, Bentley M, Marlton P, Horvath N, Lewis ID, Spencer A, Herrmann R, Arthur C, Durrant S, van Kerkhoven M. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2006, 47(11):2344-2350. 10.1080/10428190600881017, 17107908.
35. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7(5):379-391. 10.1016/S1470-2045(06)70664-7, 16648042.
36. Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001, 15(5):629-633. 10.1097/00002030-200103300-00013, 11317001.
37. Spina M, Carbone A, Vaccher E, Gloghini A, Talamini R, Cinelli R, Martellotta F, Tirelli U. Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis 2004, 38(1):142-144. 10.1086/380129, 14679461.
38. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int J Cancer 2006, 119(10):2417-2422. 10.1002/ijc.22160, 16964611.
39. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105(4):1417-1423. 10.1182/blood-2004-08-3175, 15494430.
40. Brenner H, Hakulinen T. Advanced detection of time trends in long-term cancer patient survival: experience from 50 years of cancer registration in Finland. Am J Epidemiol 2002, 156(6):556-577. 10.1093/aje/kwf071, 12226003.
41. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008, 168(5):469-476. 10.1001/archinternmed.2007.125, 18332290.
42. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23(22):5027-5033. 10.1200/JCO.2005.09.137, 15955905.
43. Cronin-Fenton DP, Sharp L, Deady S, Comber H. Treatment and survival for non-Hodgkin's lymphoma: influence of histological subtype, age, and other factors in a population-based study (1999-2001). Eur J Cancer 2006, 42(16):2786-2793. 10.1016/j.ejca.2006.04.018, 16930993.
44. Berrios-Rivera JP, Fang S, Cabanillas ME, Cabanillas F, Lu H, Du XL. Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol 2007, 30(2):163-171. 10.1097/01.coc.0000251356.63237.4f, 17414466.
45. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89(11):3909-3918.
46. Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA. Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev 2004, 13(1):138-143. 10.1158/1055-9965.EPI-03-0250, 14744745.